Liso-cel, a promising immunotherapy drug for patients battling non-Hodgkin's lymphoma, may be denied FDA approval due to COVID-19 precautions, a source says.
FDA Has Delayed Approval Process For Cancer Drug
Comment
Show comments
Hide Comments
